0001640455-18-000023.txt : 20180307
0001640455-18-000023.hdr.sgml : 20180307
20180307185909
ACCESSION NUMBER: 0001640455-18-000023
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180305
FILED AS OF DATE: 20180307
DATE AS OF CHANGE: 20180307
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MURRAY RICHARD /CA/
CENTRAL INDEX KEY: 0001242935
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37998
FILM NUMBER: 18674620
MAIL ADDRESS:
STREET 1: 22643 WOODRIDGE CT
CITY: CUPERTINO
STATE: CA
ZIP: 95014
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Jounce Therapeutics, Inc.
CENTRAL INDEX KEY: 0001640455
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 454870634
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 780 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 857-259-3840
MAIL ADDRESS:
STREET 1: 780 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
wf-form4_152046712640185.xml
FORM 4
X0306
4
2018-03-05
0
0001640455
Jounce Therapeutics, Inc.
JNCE
0001242935
MURRAY RICHARD /CA/
C/O JOUNCE THERAPEUTICS, INC.
780 MEMORIAL DRIVE
CAMBRIDGE
MA
02139
1
1
0
0
CEO and President
Common Stock
2018-03-05
4
M
0
16334
0.48
A
16334
D
Common Stock
2018-03-05
4
S
0
12100
21.21
D
4234
D
Common Stock
2018-03-05
4
S
0
4234
22.06
D
0
D
Stock Option (Right to Buy)
0.48
2018-03-05
4
M
0
16334
0
D
2024-06-26
Common Stock
16334.0
873503
D
The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 8, 2017. The Reporting Person exercised no discretion with respect to the trades.
Represents the weighted average share price of an aggregate total of 12,100 shares sold in the price range of $20.71 to $21.69 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Represents the weighted average share price of an aggregate total of 4,234 shares sold in the price range of $21.82 to $22.22 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
25% of the option shares vested and became exercisable on July 14, 2015 and the remainder of the option shares vest and become exercisable in 36 monthly installments thereafter.
/s/ Anna L. Barry, Attorney-in-Fact
2018-03-07